Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

1(16.7%)

Phase 3

1(16.7%)

6Total

Phase 1(4)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06507813Phase 3Completed

Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza

Role: lead

NCT06342921Phase 2Completed

ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection

Role: lead

NCT06589635Phase 1Completed

A Drug-Drug Interaction (DDI) Study of ADC189 With Itraconazole in Healthy, Adult Subjects

Role: lead

NCT06485401Phase 1Completed

To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function Subjects

Role: lead

NCT06360796Phase 1Completed

Study of Pharmacokinetics and Metabolism on [(14)C]ADC189

Role: lead

NCT06428903Phase 1Completed

Comparative Bioavailability Study of Tablet and Granule Formulations of ADC189 and the Study of Ultra-high Dose

Role: lead

All 6 trials loaded